Bartalena L, Brogioni S, Grasso L, Martino E
Istituto di Endocrinologia, Università di Pisa, Italy.
J Endocrinol Invest. 1993 Mar;16(3):213-8. doi: 10.1007/BF03344951.
Interleukin-6 (IL-6) is the main mediator of the acute phase response. Increased serum concentrations of the cytokine have been found in patients with nonthyroidal inflammatory disorders and infections. In 18 patients with subacute thyroiditis (SAT) evaluated within 1-2 weeks after the onset of the disease, serum IL-6 values, as assessed by an ELISA method having a limit of detection of 25 fmol/L, ranged 139.2-543.9 fmol/L (mean +/- SE, 287.2 +/- 28.2 fmol/L). These values were significantly higher than those of 25 normal healthy controls (mean +/- SE, 26.2 +/- 5.5 fmol/L, range < 25-99.4), 18 of whom had serum IL-6 values below the detection limit. The increase in serum IL-6 levels in SAT patients appeared to be related to the inflammatory disorder and not to thyrotoxicosis, because 18 Graves' disease patients and 13 patients with toxic adenoma or toxic multinodular goiter had significantly lower serum IL-6 concentrations (101.7 +/- 35.2 fmol/L, range < 25-251, for Graves' disease, 79.6 +/- 41.4 fmol/L, range < 25-168.5, for toxic adenoma, p < 0.001 vs SAT for both groups) despite the markedly higher levels of total and free thyroid hormones. Neither free T4 nor free T3 values were correlated with serum IL-6 levels both in SAT and Graves' patients. Twelve SAT patients were reevaluated 3-4 months later, after remission of the disease and at least one month after glucocorticoid withdrawal. At the final observation, all SAT patients showed a normalization of IL-6 concentration, which was undetectable in 8/12 (mean +/- SE, 22.8 +/- 5.4 fmol/L, p < 0.001 vs acute phase values).(ABSTRACT TRUNCATED AT 250 WORDS)
白细胞介素-6(IL-6)是急性期反应的主要介质。在患有非甲状腺炎性疾病和感染的患者中发现细胞因子的血清浓度升高。在疾病发作后1 - 2周内评估的18例亚急性甲状腺炎(SAT)患者中,通过检测限为25 fmol/L的ELISA方法评估,血清IL-6值在139.2 - 543.9 fmol/L范围内(平均值±标准误,287.2±28.2 fmol/L)。这些值显著高于25名正常健康对照者(平均值±标准误,26.2±5.5 fmol/L,范围<25 - 99.4),其中18名对照者的血清IL-6值低于检测限。SAT患者血清IL-6水平的升高似乎与炎性疾病有关,而非甲状腺毒症,因为18例格雷夫斯病患者以及13例毒性腺瘤或毒性多结节性甲状腺肿患者的血清IL-6浓度显著更低(格雷夫斯病患者为101.7±35.2 fmol/L,范围<25 - 251;毒性腺瘤患者为79.6±41.4 fmol/L,范围<25 - 168.5,两组与SAT相比p<0.001),尽管其总甲状腺激素和游离甲状腺激素水平明显更高。在SAT患者和格雷夫斯病患者中,游离T4和游离T3值均与血清IL-6水平无关。3 - 4个月后,在疾病缓解且停用糖皮质激素至少1个月后,对12例SAT患者进行了重新评估。在最后一次观察时,所有SAT患者的IL-6浓度均恢复正常,8/12的患者检测不到IL-6(平均值±标准误,22.8±5.4 fmol/L,与急性期值相比p<0.001)。(摘要截断于250字)